Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Recurrent Malignant Glioma

NCT00004113
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 30, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

Robotic Rehabilitation of the Upper Limb in Subacute Stroke

NCT06839482
View directory record Official record
Conditions
Stroke
Interventions
Robotic Assisted Upper Limb Rehabilitation, Control Group (CG)
Device · Other
Lead sponsor
IRCCS San Raffaele Roma
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional

GYNecologic Cancer-Related COGnitive Impairment

NCT06662435
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Interventions
GYNCOG
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prehospital Provider Training With Augmented Reality (AR)

NCT05686590
View directory record Official record
Conditions
Hypoglycemia, Pediatric ALL
Interventions
Augmented Reality Headset
Behavioral
Lead sponsor
Thomas Caruso
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Mountain View, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

NCT00809250
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Interventions
GM-K562/leukemia cell vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

NCT04516291
View directory record Official record
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions
Vupanorsen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
59
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 9:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

NCT04069195
View directory record Official record
Conditions
Inflammation, Pregnancy Related
Interventions
DHA supplement, Corn Oil: Soybean Oil
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrative Medicine for Hypermobility Spectrum Disorder and Ehlers-Danlos Syndromes (IMforHSDandEDS)

NCT04734041
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Hypermobile EDS (hEDS), Hypermobility Syndrome, EDS
Interventions
Anti-inflammatory (Mediterranean-style) diet, Behavioral and psychosocial support
Behavioral
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 30, 2026, 9:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154
View directory record Official record
Conditions
Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Revumenib, Mezigdomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

Intervention to Enhance Coping and Help-seeking Among Youth in Foster Care

NCT06019377
View directory record Official record
Conditions
Adolescent Behavior, Psychosocial Functioning, Coping Behavior, Help-Seeking Behavior, Utilization, Health Care, Depression, Anxiety, Stress Disorders, Post-Traumatic, Emotion Regulation, Child Welfare
Interventions
Stronger Youth Networks and Coping (SYNC)
Behavioral
Lead sponsor
Portland State University
Other
Eligibility
16 Years to 20 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hydration Intervention in Children

NCT04265300
View directory record Official record
Conditions
Dehydration in Children
Interventions
Creative Roots
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
7 Years to 12 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Changing Health Through Food Support for Diabetes

NCT04959487
View directory record Official record
Conditions
Type 2 Diabetes, Food Insecurity
Interventions
Food support, Nutritional Counseling and education
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GLOW Study: Effects of Triple Protein in Women

NCT07526571
View directory record Official record
Conditions
Healthy Women
Interventions
Triple protein support, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy

NCT02391324
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Lokomat (LOK), Gait focused physical therapy (fPT), LOK + fPT
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
5 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Treatment of CFS & Fibromyalgia With Recovery Factors

NCT04381793
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome
Interventions
Recovery Factors
Dietary Supplement
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kailua, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 9:20 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

NCT00889655
View directory record Official record
Conditions
Colonoscopy
Interventions
Golytely (polyethylene glycol), MiraLax (polyethylene glycol 3350)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 30, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama

NCT04604743
View directory record Official record
Conditions
Vaccine Refusal
Interventions
Intervention, TBN
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years to 26 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Fecal Microbiota Transplant (FMT) in Melanoma Patients

NCT03341143
View directory record Official record
Conditions
Melanoma
Interventions
Fecal Microbiota Transplant with Pembrolizumab
Drug
Lead sponsor
Zarour, Hassane, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

NCT00768690
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333, ketoconazole, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 30, 2026, 9:20 PM EDT